NCT01478373 - Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

Dovitinib (TKI258)

Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.

Trial Locations (15)

Novartis Investigative Site, Candiolo

Novartis Investigative Site, Torino

Novartis Investigative Site, Milan

Novartis Investigative Site, Bordeaux

Novartis Investigative Site, Essen

Novartis Investigative Site, Reims

Novartis Investigative Site, Lille

Novartis Investigative Site, Lyon

Novartis Investigative Site, Villejuif

Novartis Investigative Site, HUS

Novartis Investigative Site, Roma

Novartis Investigative Site, Palma de Mallorca

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Barcelona

Novartis Investigative Site, L'Hospitalet de Llobregat